RE: The J.P. Morgan Healthcare Conference6 Jan 2026 09:36
Great Post
This is all that matters;
A groundbreaking patent application for its lead asset P140, the world's first "Immunormalizer." The patent application which provides the potential for 20 years of commercial exclusivity, discloses a novel diagnostic test and precision treatment approach, identifying a subpopulation of patients with Type M immune disorder that are P140 super-responders. This approach can be used to treat up to 50 autoimmune diseases ("AutoIDs"), representing a major step forward in precision medicine.
THIS IS A GAME CHANGER
The discovery of a NEW mechanism of action and identification of Type M, a sub-type of auto-immune disorders, greatly expands the scope of P140 across a wide range of autoimmune diseases. This discovery significantly enhances the business case due to the potential for long-term increased revenues.
This combination makes P140 a unique and extremely valuable asset, particularly with the potential for 20 years of commercial exclusivity, and will add enormous traction to our current discussions with potential global partners of P140.
Dr Sébastien Goudreau CSO of ImmuPharma, "We are delighted that our innovative research methods have provided the internally generated (and externally validated) scientific data to support this new patent application on P140, proving that our research approach is highly effective in the extremely competitive landscape of pharmaceutical development.
Expecting a huge announcement in Q1 relating to pharma deal, substantial upfront payment to IMM and ongoing long term royalties.
Nobody knows exactly when. Patience is the key. But when the news drops.....................
MASSIVE re-rate